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Abstract
Introduction Bisphosphonates are used worldwide to treat
osteoporosis and, thus, to prevent fractures. Though they
have been proven in clinical trials to avoid some fractures,
their effectiveness in reducing hip fractures is unclear. The
aim of the present study was to explore the relationship
between bisphosphonate use and hip fracture trends in
Spain.
Methods For this purpose, an ecologic study spanning 2002
to 2008 was conducted in Spain. Consumption data were
obtained from the Spanish Ministry of Health and Social
Policy. The number of hip fractures was obtained from
hospital discharges; annual hip fracture rates were deter-
mined and standardized using the Spanish 2002 population
census. A linear regression was performed between fracture
rate and use of bisphosphonates; R2 and Pearson correlation
coefficient were calculated.
Results From 2002 to 2008, dispensed prescriptions of
bisphosphonates in Spain increased from 3.28 to 17.66
DDD/1,000 inhabitants per day. In the same period, the
crude hip fracture rate increased from 2.85 to 3.02 cases
per 1,000 inhabitants older than 50 years; however, when
age standardized rates were estimated, the rate declined
from 2.85 to 2.79. Analyzed by sex, the standardized rate
for men slightly increased from 1.45 to 1.48, while for
women the rate significantly dropped from 4.00 to 3.91.
Conclusion A small effect of bisphosphonates on hip frac-
ture rates can not be ruled out; however, other factors might
partially explain this decline. Assuming this medication was
the only cause for hip fracture rate reduction, the elevated
medication cost to avoid a single hip fracture makes it
necessary to explore less expensive interventions.
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Introduction
Hip fractures are common in the elderly and are associated
with a high morbidity and mortality [1]; older adults have a
five- to eightfold increased risk for all-cause mortality dur-
ing the first 3 months after hip fracture [2]. A review of the
outcomes after hip fracture over a 40-year period (1959–
1998) showed that, in this period, mortality remained essen-
tially unchanged at 6 and 12 months after the fracture [3].
The population over 50 years of age has significantly
increased worldwide in recent years. In Spain, it increased
by 18.9% over the period 2000–2009 [4]; the population older
than 85 years increased by 42.4% in the same period. The
elderly population is more vulnerable to certain diseases; for
instance, it has been estimated that almost 4 million people in
Spain might currently suffer from osteoporosis [5]. Osteopo-
rosis in turn is associated with a high risk of fractures—the
most troublesome being hip fractures—and disability, and
with substantial medical costs. In an attempt to reduce this
enormous disease burden, osteoporosis is widely treated in
order to prevent fractures; bisphosphonates are the medica-
tions most used for this goal [6]. However, in spite of their
widespread use, their effectiveness in reducing hip fractures in
the general population is a matter of controversy [7]. More-
over, long-term treatment with bisphosphonates has recently
been associated with an increased risk of subtrochanteric or
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femoral shaft fractures, although the absolute risk of these
atypical fractures associated with bisphosphonate use seems
to be very low [8]. Therefore, the aim of the present study was
to explore the relationship between bisphosphonate use and
hip fracture trends in Spain.
Methods
For the purpose, an ecologic comparison study spanning
2002 to 2008 was conducted [9]. During that period, we
observed the evolution of both bisphosphonate consumption
and hip fracture rates in Spain. Consumption and economic
data were obtained from the DGPS (Dirección General de
Farmacia y Productos Sanitarios) database of the Spanish
Ministry of Health and Social Policy [10]. This database
offers information on the consumption and cost of the med-
ications dispensed by pharmacies at the expense of the
Spanish National Health System, which covers almost the
whole population; it does not include hospital consumption,
consumption paid by the patient or private insurers, or the
consumption of non-prescription drugs or drugs not covered
by the National Health System. This database was con-
ceived for administrative purposes: it serves to control and
follow payments to pharmacists, following a specific pro-
cess for registering prescriptions. In no way is this informa-
tion collected as in a clinical history, and the database does
not include information about age, sex or specialty of pre-
scribing physicians. The risk of duplicate or missing
information is almost null.
Data were expressed in defined daily doses (DDD) per
1,000 inhabitants per day (DDD/1,000), using the DDD
values proposed by the WHO [11, 12]. The following for-
mula was used: number of DDD per 1,000 inhabitants per
day 0 (number of packages dispensed × number of doses per
package × number of mg per dose × 1,000 inhabitants)/
(DDD in mg × number of inhabitants in the geographic area
for the year × 365 days).
Annual hip fracture rates by age and sex were calculated
and then we performed a direct standardization using the
Spanish 2002 population age distribution as a reference [4];
we used 5-year groups to perform standardization as this
provides estimates that can be compared directly from one
year to another without the confounding effects of
changes in age distribution over time. Numbers of hip
fractures were obtained from the CMBD-H (Minimum
Dataset–Hospitalization), which is publicly available at
the Spanish Ministry of Health and Social Policy web-
site [13]; the ICD-9-MC diagnosis code 820 was used.
Annual medication costs are periodically published by
this Ministry [14].
The relationship between hip fracture incidence rate
and bisphosphonate use was examined by calculating
Pearson’s correlation and by linear regression analysis.
Statistical analysis was performed using the summary.im R
function [15].
Results
Spain had 45,593,385 inhabitants as of July 1st 2008. Over
the period 2002–2008, the population older than 50 years
increased by 12.4% (women, 11.8%; men, 13.0%) and those
older than 80 years, by 28.8%. In the year 2008, this oldest
group represented 4.6% of the whole population.
From 2002 to 2008, dispensed prescriptions of
bisphosphonates in Spain increased from 3.28 to 17.66
DDD/1,000 inhabitants per day. Meanwhile, the number of
hip fractures increased from 39,920 to 47,308. In the same
period, the crude hip fracture rate increased from 2.85 to
3.02 cases per 1,000 inhabitants older than 50 years. How-
ever, when age standardized rates were estimated, the rate
declined from 2.85 to 2.79 per 1,000 inhabitants older than
50 years (Fig. 1). When analyzed by sex, the standardized
rate slightly increased in men, from 1.45 to 1.48 cases per
1,000 inhabitants older than 50 years (Fig. 2a), while it
significantly dropped in women, from 4.00 to 3.91 cases
per 1,000 inhabitants older than 50 years (Fig. 2b).
Age and gender structure of the population has changed
over the last years in Spain. Table 1 shows this structure
linked with the incidence rates of hip fractures.
Discussion
Despite the initial findings from the crude analysis, standard-
ization showed that, although weak, there was a statistically
significant correlation between increase in bisphosphonate
consumption and decline in hip fracture rates; this was
observed only in women. Whether this decline was due
to bisphosphonate use might be a matter of debate. The
fact that a decline did occur in women points to a
causal relationship, since women are the main users of
this medication. At the same time, as they show a
higher risk of hip fractures than men, they are more
prone to be the target of specific health advice or
campaigns intended to curb the number of hip fractures
in the population; furthermore, in the near 10-year period of
the study, individuals at a higher risk, when becoming aware
of such a risk, may have subtly modified their behavior and
environment.
A relevant question to be posed is that of the relationship
between benefits and costs. Assuming a beneficial effect of
bisphosphonates in hip fracture prevention and based on our
current data, we would need 83,082 DDD to avoid one
single hip fracture a year or, similarly, to continuously treat
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228 persons a year (Fig. 1b). Considering that the
average cost for these drugs was €0.919 per day in
2008 [10], the total cost to avoid a hip fracture would
be €76,352. The direct health care costs of hip fractures,
as calculated by the Spanish National Health Service,
reached €7,713 per hip fracture [13]; indirect costs of
hip fractures, cost per day deflation because of the
growing consumption of generic medications as well
as the cost relative to bisphosphonates’ adverse effects
should be also taken into account.
Fig. 1 Relationship between the
total annual number of
prescriptions (DDD/1,000
inhabitants per day) for
bisphosphonate use and
standardized hip fracture rates
(per 1,000 persons) in the
total Spanish population older
than 50 years (2002–2008)
(p00.043*; R2 00.59)
Fig. 2 Relationship between the total annual number of prescrip-
tions (DDD/1,000 inhabitants per day) for bisphosphonate use
and age-standardized hip fracture rates (per 1,000 persons) in
the total Spanish population older than 50 years (2002–2008)
for a women (p00.0198*; R2 00.70) and for b men (p00.416;
R2 00.14)
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Hip fracture is associated with high morbidity and is
widely regarded as a life-threatening event in the elderly.
The prevention of osteoporosis-associated fractures should
include fall prevention, calcium supplementation, and life-
style advice as well as, when necessary, pharmacological
therapy with agents with proven antifracture efficacy [16].
Although there is evidence of the antifracture efficacy, includ-
ing for hip fractures, of bisphosphonates in clinical trials
[17–21], observational studies examining effectiveness found
opposite results [22, 23]. In a community cohort of post-
menopausal women at risk, the fracture risk of patients who
received bisphosphonates did not differ significantly from
those who did not [21]; the same has been recently observed
in another large cohort of post-menopausal women in Spain
[23]. Moreover, atypical fractures of the femoral shaft associ-
ated with long-term bisphosphonate use have been observed
to occur [24–27].
Our results are rather close to those found in the above-
mentioned cohort studies but differed from those seen in
another ecologic study carried out in Australia [28]. In this
latter study, it was observed that a drop in the use of
bisphosphonates was associated with an increase in hip
fracture rates in women. The fact that the study referred to
a small population might explain those differences; other
explanations could be differences in medication adherence
or in secular trends in hip fractures.
Prior trends of hip fractures are important for understand-
ing the impact of bisphosphonate consumption. In the Span-
ish region of Cantabria hip fracture crude rates did increase
between 1988 and 2002 [29]; however, following age
adjustment, no significant changes were found during
that period. In our study, we observed a similar increase
in crude hip fracture rates but a mild decrease in the
standardized hip fracture trend following increased use
of bisphosphonates. In the United States, Switzerland,
Denmark, and Canada standardized hip fracture rates,
after a previous long term steady trend, are now declin-
ing; reasons seem to be more complicated than simply
increased patterns of diagnosis and treatment for osteoporosis,
and some factors such as changing smoking habits, obesity,
improved general health conditions, vitamin D supplementa-
tion, and institution-dwelling should be considered [7, 30–32].
Our study has some limitations. First, there may be
inaccurate reasoning since ecologic studies focus on the
comparison of groups, rather than on individuals. Second,
there may also be a temporal ambiguity: the time trend
studied and bisphosphonate efficacy associated with hip
fractures rates may have different latent periods. A third
limitation is that ecologic studies do not provide information
about different etiologic agents that contribute to hip frac-
ture rates, such us proton pump inhibitors, psychotropic
medications, corticosteroids, etc, and we were therefore
Table 1 Incidence rates of hip
fractures per 1,000 persons
older than 50 years in the
Spanish population
Age group (years) 2002 2003 2004 2005 2006 2007 2008
Men 50–54 0.22 0.21 0.19 0.20 0.22 0.22 0.20
55–59 0.27 0.32 0.29 0.29 0.27 0.28 0.27
60–64 0.40 0.39 0.40 0.45 0.39 0.43 0.42
65–69 0.68 0.70 0.61 0.65 0.66 0.63 0.66
70–74 1.31 1.33 1.23 1.32 1.29 1.23 1.26
75–79 2.80 2.78 2.76 2.72 2.54 2.71 2.68
80–84 5.52 5.67 5.82 5.90 5.75 5.86 6.03
85–89 10.20 10.94 10.61 10.62 10.96 11.17 11.41
90–94 16.89 17.06 16.76 17.42 17.09 17.32 17.42
95+ 21.67 22.16 22.39 21.85 22.70 24.21 22.17
All 1.45 1.51 1.49 1.55 1.53 1.59 1.62
Women 50–54 0.13 0.13 0.14 0.14 0.13 0.14 0.14
55–59 0.26 0.28 0.26 0.28 0.25 0.28 0.27
60–64 0.51 0.49 0.52 0.46 0.49 0.57 0.51
65–69 1.14 1.19 1.12 1.10 1.04 0.99 1.00
70–74 2.79 2.81 2.65 2.56 2.51 2.61 2.44
75–79 6.35 6.43 6.40 6.25 6.04 6.10 5.98
80–84 12.84 12.75 12.39 13.00 12.71 12.65 12.45
85–89 21.08 21.45 21.18 21.35 21.44 21.76 21.69
90–94 28.69 28.45 28.41 28.62 28.92 28.66 28.94
95+ 29.27 30.52 30.31 30.84 30.23 31.68 33.26
All 4.00 4.08 4.06 4.14 4.13 4.22 4.20
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unable to control for all of them. A fourth limitation is the
method used to calculate drug consumption figures: DDD is
an approximate unit of measurement and does not necessar-
ily reflect the real daily dose consumed. A fifth limitation is
the quality of the information; databases of the Spanish
Ministry of Health and Social Policy do not include con-
sumption in hospitals, so our results refer exclusively to the
consumption in the primary care or non-hospital setting;
also, the database we used does not include prescriptions
written by insurance companies or private practitioners;
however, the almost universal coverage of the Spanish
National Health System and the almost certain hospital-
ization of people with hip fractures minimize this pos-
sible bias. The consumption data do not include the
gender of the person who received the prescriptions;
thus, we were unable to analyze the use of these med-
ications separately by men and women. To explore the
relationship with hip fracture rates in men and women
we assumed a similar evolution of bisphosphonate con-
sumption in both sexes. Finally, the CMBD is a data-
base originally intended for administrative purposes;
however, it has been validated and is currently and
widely used for epidemiological studies [33]. At the
same time, our overall estimate of 2.8 cases per 1,000
inhabitants older than 50 years in 2002 is very similar
to that of Hernández in Cantabria (Spain) of 2.6 cases
per 1,000 inhabitants [29]. The latter estimate was made
through clinical records from emergency units and the
orthopedic surgical units of all hospitals in Cantabria along
with admission and discharge files from these hospitals
In summary, the substantial increase in bisphosphonate
use in Spain from 2002 to 2008 weakly but significantly
correlates with a drop (2.2%) in standardized hip fracture
rates in women during that period. An effect of this medi-
cation on hip fracture reduction can not be ruled out; nev-
ertheless, other factors could partially explain this decline,
i.e., lifestyle advice, particular health campaigns, self-
awareness, improvement in residence conditions, calcium
supplementation, dietetic changes, or institution-dwelling
[30]. All in all, even assuming that bisphosphonates were
the only cause for hip fracture rate reduction, the elevated
medication cost to avoid a single hip fracture makes it
necessary to explore less expensive interventions.
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